Relative Value Partners Group’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | $7.5M | Buy |
8,287
+6,520
| +369% | +$5.22M | 0.97% | 20 |
|
|
2024
Q1 | $1.14M | Sell |
1,767
-24
| -1% | -$17.1K | 0.07% | 142 |
|
|
2023
Q4 | $1.04M | Buy |
1,791
+60
| +3% | +$35K | 0.06% | 148 |
|
|
2023
Q3 | $930K | Buy |
1,731
+545
| +46% | +$281K | 0.06% | 144 |
|
|
2023
Q2 | $556K | Hold |
1,186
| – | – | 0.04% | 176 |
|
|
2023
Q1 | $407K | Sell |
1,186
-588
| -33% | -$198K | 0.03% | 190 |
|
|
2022
Q4 | $649K | Buy |
1,774
+538
| +44% | +$191K | 0.05% | 175 |
|
|
2022
Q3 | $400K | Buy |
+1,236
| New | +$392K | 0.03% | 188 |
|
|
2022
Q2 | – | Sell |
-1,119
| Closed | -$320K | – | 222 |
|
|
2022
Q1 | $320K | Hold |
1,119
| – | – | 0.02% | 206 |
|
|
2021
Q4 | $309K | Hold |
1,119
| – | – | 0.02% | 161 |
|
|
2021
Q3 | $259K | Hold |
1,119
| – | – | 0.02% | 168 |
|
|
2021
Q2 | $257K | Hold |
1,119
| – | – | 0.02% | 166 |
|
|
2021
Q1 | $209K | Sell |
1,119
-1,300
| -54% | -$254K | 0.02% | 191 |
|
|
2020
Q4 | $408K | Buy |
2,419
+102
| +4% | +$15.2K | 0.04% | 147 |
|
|
2020
Q3 | $343K | Sell |
2,317
-100
| -4% | -$15.5K | 0.04% | 139 |
|
|
2020
Q2 | $397K | Hold |
2,417
| – | – | 0.04% | 126 |
|
|
2020
Q1 | $335K | Hold |
2,417
| – | – | 0.04% | 135 |
|
|
2019
Q4 | $318K | Buy |
2,417
+117
| +5% | +$13.6K | 0.03% | 134 |
|
|
2019
Q3 | $257K | Buy |
2,300
+140
| +6% | +$15.6K | 0.03% | 138 |
|
|
2019
Q2 | $239K | Sell |
2,160
-130
| -6% | -$15.3K | 0.03% | 147 |
|
|
2019
Q1 | $297K | Sell |
2,290
-210
| -8% | -$25.5K | 0.03% | 134 |
|
|
2018
Q4 | $289K | Hold |
2,500
| – | – | 0.03% | 125 |
|
|
2018
Q3 | $268K | Hold |
2,500
| – | – | 0.03% | 128 |
|
|
2018
Q2 | $213K | Buy |
+2,500
| New | +$205K | 0.02% | 135 |
|
|
2018
Q1 | – | Sell |
-2,500
| Closed | -$211K | – | 147 |
|
|
2017
Q4 | $211K | Hold |
2,500
| – | – | 0.02% | 119 |
|
|
2017
Q3 | $214K | Hold |
2,500
| – | – | 0.02% | 107 |
|
|
2017
Q2 | $206K | Hold |
2,500
| – | – | 0.02% | 114 |
|
|
2017
Q1 | $212K | Buy |
+2,500
| New | +$200K | 0.03% | 124 |
|
|
2016
Q4 | – | Sell |
-2,500
| Closed | -$201K | – | 143 |
|
|
2016
Q3 | $201K | Buy |
+2,500
| New | +$200K | 0.03% | 122 |
|
|
2016
Q2 | – | Sell |
-2,500
| Closed | -$211K | – | 134 |
|
|
2016
Q1 | $211K | Hold |
2,500
| – | – | 0.03% | 123 |
|
|
2015
Q4 | $211K | Hold |
2,500
| – | – | 0.03% | 124 |
|
|
2015
Q3 | $209K | Hold |
2,500
| – | – | 0.03% | 118 |
|
|
2015
Q2 | $209K | Buy |
+2,500
| New | +$190K | 0.02% | 107 |
|
Other funds holding LLY
Relative Value Partners Group's LLY Position: Q2 2024 in Review
Relative Value Partners Group increased its Eli Lilly (LLY) stake by 369% in Q2 2024, buying an estimated $5.22M and bringing the position to 8,287 shares worth $7.5M. The position accounts for 0.97% of the portfolio, ranked #20.
Relative Value Partners Group first reported a position in LLY in Q2 2015 and has held it in 33 quarters since. 3,565 funds tracked by Wall St. Rank hold LLY as of Q2 2024.
- Relative Value Partners Group held 8,287 shares of Eli Lilly worth $7.5M as of Q2 2024.
- Relative Value Partners Group bought 6,520 Eli Lilly shares in Q2 2024, an estimated $5.22M.
- Eli Lilly made up 0.97% of Relative Value Partners Group's portfolio in Q2 2024, its #20 holding.
- Relative Value Partners Group first reported a position in Eli Lilly in Q2 2015 and has held it in 33 quarters since.
- 3,565 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2024.
Based on Relative Value Partners Group's 13F filing for Q2 2024, filed 12 Jul 2024.